organon & co. - OGN
OGN
Close Chg Chg %
14.89 0.25 1.70%
Open Market
15.14
+0.25 (1.70%)
Volume: 591.55K
Last Updated:
Nov 22, 2024, 11:28 AM EDT
Company Overview: organon & co. - OGN
OGN Key Data
| Open $14.94 | Day Range 14.94 - 15.21 |
| 52 Week Range 10.84 - 23.10 | Market Cap $3.83B |
| Shares Outstanding 257.54M | Public Float 256.97M |
| Beta 0.80 | Rev. Per Employee N/A |
| P/E Ratio 2.95 | EPS $5.07 |
| Yield 752.18% | Dividend $0.28 |
| EX-DIVIDEND DATE Nov 12, 2024 | SHORT INTEREST N/A |
| AVERAGE VOLUME 3.02M |
OGN Performance
| 1 Week | -0.93% | ||
| 1 Month | -13.23% | ||
| 3 Months | -33.41% | ||
| 1 Year | 31.07% | ||
| 5 Years | N/A |
OGN Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
9
Full Ratings ➔
About organon & co. - OGN
Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
OGN At a Glance
Organon & Co.
30 Hudson Street
Jersey City, New Jersey 07302
| Phone | 1-551-430-6900 | Revenue | 6.26B | |
| Industry | Pharmaceuticals: Major | Net Income | 1.02B | |
| Sector | Health Technology | 2023 Sales Growth | 1.442% | |
| Fiscal Year-end | 12 / 2024 | Employees | 10,000 | |
| View SEC Filings |
OGN Valuation
| P/E Current | 2.953 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 3.612 |
| Price to Sales Ratio | 0.59 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | 4.625 |
| Enterprise Value to EBITDA | 7.635 |
| Enterprise Value to Sales | 1.905 |
| Total Debt to Enterprise Value | 0.748 |
OGN Efficiency
| Revenue/Employee | 626,300.00 |
| Income Per Employee | 102,300.00 |
| Receivables Turnover | 3.373 |
| Total Asset Turnover | 0.544 |
OGN Liquidity
| Current Ratio | 1.545 |
| Quick Ratio | 1.094 |
| Cash Ratio | 0.237 |
OGN Profitability
| Gross Margin | 59.844 |
| Operating Margin | 21.188 |
| Pretax Margin | 10.746 |
| Net Margin | 16.334 |
| Return on Assets | 8.891 |
| Return on Equity | N/A |
| Return on Total Capital | 11.545 |
| Return on Invested Capital | 12.057 |
OGN Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | 100.79 |
| Total Debt to Total Assets | 74.067 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 100.169 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Organon & Co. - OGN
Collapse All in section
| All values USD millions. | 2020 | 2021 | 2022 | 2023 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 8.10B | 6.36B | 6.17B | 6.26B | |
Sales Growth
| -15.05% | -21.44% | -2.92% | +1.44% | |
Cost of Goods Sold (COGS) incl D&A
| 3.34B | 2.38B | 2.28B | 2.52B | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 157.00M | 195.00M | 212.00M | 236.00M | |
Depreciation
| 72.00M | 92.00M | 96.00M | 120.00M | |
Amortization of Intangibles
| 85.00M | 103.00M | 116.00M | 116.00M | |
COGS Growth
| -7.47% | -28.77% | -4.28% | +10.31% | |
Gross Income
| 4.75B | 3.98B | 3.89B | 3.75B | |
Gross Income Growth
| -19.68% | -16.29% | -2.11% | -3.75% | |
Gross Profit Margin
| +58.70% | +62.55% | +63.07% | +59.84% |
| 2020 | 2021 | 2022 | 2023 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 1.97B | 2.11B | 2.17B | 2.42B | |
Research & Development
| 304.00M | 443.00M | 471.00M | 528.00M | |
Other SG&A
| 1.67B | 1.66B | 1.70B | 1.89B | |
SGA Growth
| -12.60% | +6.90% | +3.28% | +11.31% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| 125.00M | 96.00M | 149.00M | 70.00M | |
EBIT after Unusual Expense
| 2.66B | 1.78B | 1.57B | 1.26B | |
Non Operating Income/Expense
| 29.00M | 11.00M | (26.00M) | (57.00M) | |
Non-Operating Interest Income
| - | - | - | 16.00M | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 6.00M | 258.00M | 422.00M | 527.00M | |
Interest Expense Growth
| - | +4,200.00% | +63.57% | +24.88% | |
Gross Interest Expense
| 6.00M | 258.00M | 422.00M | 527.00M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| 2.68B | 1.53B | 1.12B | 673.00M | |
Pretax Income Growth
| -24.61% | -42.95% | -26.62% | -40.02% | |
Pretax Margin
| +33.10% | +24.04% | +18.17% | +10.75% | |
Income Tax
| 520.00M | 178.00M | 205.00M | (350.00M) | |
Income Tax - Current - Domestic
| 102.00M | 31.00M | 51.00M | 48.00M | |
Income Tax - Current - Foreign
| 412.00M | 435.00M | 172.00M | 87.00M | |
Income Tax - Deferred - Domestic
| 10.00M | (68.00M) | (40.00M) | (57.00M) | |
Income Tax - Deferred - Foreign
| (4.00M) | (220.00M) | 22.00M | (428.00M) | |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| 2.16B | 1.35B | 917.00M | 1.02B | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| 2.16B | 1.35B | 917.00M | 1.02B | |
Net Income Growth
| -32.88% | -37.45% | -32.12% | +11.56% | |
Net Margin Growth
| +26.68% | +21.24% | +14.85% | +16.33% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| 2.16B | 1.35B | 917.00M | 1.02B | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| 2.16B | 1.35B | 917.00M | 1.02B | |
EPS (Basic)
| 8.5331 | 5.3283 | 3.6091 | 4.008 | |
EPS (Basic) Growth
| -32.88% | -37.56% | -32.27% | +11.05% | |
Basic Shares Outstanding
| 253.13M | 253.55M | 254.08M | 255.24M | |
EPS (Diluted)
| 8.5331 | 5.3283 | 3.5937 | 3.9919 | |
EPS (Diluted) Growth
| -32.88% | -37.56% | -32.55% | +11.08% | |
Diluted Shares Outstanding
| 253.13M | 253.55M | 255.17M | 256.27M | |
EBITDA
| 2.94B | 2.07B | 1.93B | 1.56B | |
EBITDA Growth
| -26.82% | -29.67% | -6.58% | -19.06% | |
EBITDA Margin
| +36.30% | +32.50% | +31.28% | +24.96% |
Snapshot
| Average Recommendation | HOLD | Average Target Price | 22.375 | |
| Number of Ratings | 9 | Current Quarters Estimate | 0.926 | |
| FY Report Date | 12 / 2024 | Current Year's Estimate | 4.124 | |
| Last Quarter’s Earnings | 0.87 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 4.14 | Next Fiscal Year Estimate | 4.236 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 7 | 4 | 8 | 8 |
| Mean Estimate | 0.93 | 1.03 | 4.12 | 4.24 |
| High Estimates | 1.14 | 1.10 | 4.30 | 4.74 |
| Low Estimate | 0.81 | 0.92 | 4.02 | 3.55 |
| Coefficient of Variance | 12.45 | 8.46 | 2.29 | 8.08 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 2 | 3 | 3 |
| OVERWEIGHT | 1 | 1 | 1 |
| HOLD | 4 | 4 | 5 |
| UNDERWEIGHT | 1 | 1 | 1 |
| SELL | 1 | 1 | 0 |
| MEAN | Hold | Hold | Overweight |
SEC Filings for Organon & Co. - OGN
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Organon & Co. - OGN
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Jun 12, 2024 | Carrie Smith Cox Director | 47,060 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 12, 2024 | Rochelle B. Lazarus Director | 36,455 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 12, 2024 | Robert A. Essner Director | 36,455 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 12, 2024 | Martha E. McGarry Director | 36,455 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 12, 2024 | Helene D. Gayle Director | 36,455 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 12, 2024 | Shalini Sharp Director | 36,784 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 12, 2024 | R. Alan B. Ezekowitz Director | 36,455 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 12, 2024 | Deborah R. Leone Director | 36,455 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 12, 2024 | Grace Puma Whiteford Director | 36,455 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 12, 2024 | Cynthia M. Patton Director | 36,455 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 12, 2024 | Philip O. Ozuah Director | 36,455 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| May 8, 2024 | Susanne Gabriele Fiedler Chief Commercial Officer | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 8, 2024 | Susanne Gabriele Fiedler Chief Commercial Officer | 50,664 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $19.61 per share | 993,521.04 |
| May 8, 2024 | Susanne Gabriele Fiedler Chief Commercial Officer | 52,253 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 8, 2024 | Kirke Weaver Gen. Counsel & Corp. Secy. | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 8, 2024 | Rachel A. Stahler Chief Information Officer | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 8, 2024 | Rachel A. Stahler Chief Information Officer | 48,237 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $19.61 per share | 945,927.57 |
| May 8, 2024 | Rachel A. Stahler Chief Information Officer | 49,282 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 8, 2024 | Matthew M. Walsh Chief Financial Officer | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 8, 2024 | Matthew M. Walsh Chief Financial Officer | 88,326 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $19.61 per share | 1,732,072.86 |